Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy

M. Fernanda Amary, Hongtao Ye, Fitim Berisha, Bhavisha Khatri, Georgina Forbes, Katie Lehovsky, Anna M. Frezza, Sam Behjati, Patrick Tarpey, Nischalan Pillay, Peter J. Campbell, Roberto Tirabosco, Nadège Presneau, Sandra J. Strauss, Adrienne M. Flanagan

Research output: Contribution to journalArticle

Abstract

Osteosarcoma, the most common primary bone sarcoma, is a genetically complex disease with no widely accepted biomarker to allow stratification of patients for treatment. After a recent report of one osteosarcoma cell line and one tumor exhibiting fibroblastic growth factor receptor 1 (FGFR1) gene amplification, the aim of this work was to assess the frequency of FGFR1 amplification in a larger cohort of osteosarcoma and to determine if this biomarker could be used for stratification of patients for treatment. About 352 osteosarcoma samples from 288 patients were analyzed for FGFR1 amplification by interphase fluorescence in situ hybridization. FGFR1 amplification was detected in 18.5% of patients whose tumors revealed a poor response to chemotherapy, and no patients whose tumors responded well to therapy harbored this genetic alteration. FGFR1 amplification is present disproportionately in the rarer histological variants of osteosarcoma. This study provides a rationale for inclusion of patients with osteosarcoma in clinical trials using FGFR kinase inhibitors.

Original languageEnglish
Pages (from-to)980-987
Number of pages8
JournalCancer Medicine
Volume3
Issue number4
DOIs
Publication statusPublished - 2014

Keywords

  • Amplification
  • FGFR
  • FGFR1
  • FISH
  • Genetics
  • Osteosarcoma
  • Polysomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Fernanda Amary, M., Ye, H., Berisha, F., Khatri, B., Forbes, G., Lehovsky, K., Frezza, A. M., Behjati, S., Tarpey, P., Pillay, N., Campbell, P. J., Tirabosco, R., Presneau, N., Strauss, S. J., & Flanagan, A. M. (2014). Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Medicine, 3(4), 980-987. https://doi.org/10.1002/cam4.268